Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3b Open-label Study of the Anti-FGF23 Antibody, Burosumab (KRN23) in Adult Patients With X-linked Hypophosphatemia (XLH)

Next Previous
Trial Profile

A Phase 3b Open-label Study of the Anti-FGF23 Antibody, Burosumab (KRN23) in Adult Patients With X-linked Hypophosphatemia (XLH)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Burosumab (Primary) ; Burosumab (Primary) ; Burosumab (Primary)
  • Indications X-linked dominant hypophosphataemic rickets
  • Focus Therapeutic Use
  • Sponsors Kyowa Kirin Pharmaceutical Development

Most Recent Events

  • 19 May 2022 Status changed from active, no longer recruiting to completed.
  • 03 Dec 2021 Results of post-hoc analysis (n=131) assessing utility change over time was estimated using asymptotic models fitted to the placebo data to week 24 from UX023-CL303, and the burosumab data to week 48 from BUR02 studies, presented at the 24th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
  • 31 Aug 2021 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top